What Are the Side Effects of Wegovy? The Complete Clinical Profile from Common to Rare

Trust signals

> Reviewed by FormBlends Medical Team · Last updated April 2026 · 14 sources cited

Key Takeaways

• Nausea affects 44% of Wegovy patients in clinical trials, typically peaking 2-4 days post-injection and resolving within 12-16 weeks at stable doses
• Serious side effects (pancreatitis, gallbladder disease, severe hypoglycemia) occur in under 2% of patients but require immediate medical attention
• Most GI side effects follow a predictable dose-response pattern, worsening during escalation and improving with adaptation time
• The side effect profile of compounded semaglutide matches brand-name Wegovy because the active ingredient and mechanism are identical

Direct answer (40-60 words)

Wegovy's most common side effects are gastrointestinal: nausea (44%), diarrhea (30%), vomiting (24%), constipation (24%), and abdominal pain (20%). Most occur during dose escalation and resolve within 12-16 weeks. Serious but rare side effects include pancreatitis (0.2%), gallbladder disease (1.6%), and severe allergic reactions. About 7% of patients discontinue treatment due to side effects.

Table of contents

1. The complete side effect frequency table from STEP trials
2. Why most Wegovy side effects happen (the GLP-1 mechanism)
3. The predictable timeline: when side effects start, peak, and resolve
4. Common side effects and their management protocols
5. What most articles get wrong about "permanent" side effects
6. Serious side effects that require immediate medical attention
7. The dose-response relationship: does higher dose mean worse side effects?
8. FormBlends clinical pattern: the three-phase adaptation model
9. Side effects unique to injection site vs systemic effects
10. When side effects mean you should stop vs adjust
11. The decision tree: managing vs escalating side effect concerns
12. FAQ
13. Sources

The complete side effect frequency table from STEP trials

The STEP clinical trial program (STEP 1-5, N = 4,567 patients) provides the most comprehensive side effect data for semaglutide 2.4 mg (Wegovy's dose). Here's the complete profile:

Side Effect	Wegovy 2.4 mg	Placebo	Difference
Nausea	44.2%	17.0%	+27.2%
Diarrhea	30.2%	15.8%	+14.4%
Vomiting	24.8%	6.2%	+18.6%
Constipation	24.4%	11.1%	+13.3%
Abdominal pain	20.3%	9.8%	+10.5%
Headache	14.0%	12.5%	+1.5%
Fatigue	11.3%	6.9%	+4.4%
Dyspepsia (indigestion)	9.8%	4.6%	+5.2%
Dizziness	8.2%	5.3%	+2.9%
Abdominal distension	7.0%	3.5%	+3.5%
Eructation (belching)	6.9%	1.9%	+5.0%
Flatulence	6.1%	3.2%	+2.9%
Gastroesophageal reflux	5.7%	3.6%	+2.1%
Gastritis	3.9%	1.8%	+2.1%

Serious adverse events occurred in 9.8% of Wegovy patients vs 6.4% of placebo. Treatment discontinuation due to side effects: 7.0% Wegovy vs 3.1% placebo (Wilding et al., New England Journal of Medicine, 2021).

The pattern is clear: GI side effects dominate. Neurological side effects (headache, dizziness) show minimal signal above placebo. The medication's effects concentrate in the digestive system because that's where GLP-1 receptors are most densely expressed.

Why most Wegovy side effects happen (the GLP-1 mechanism)

Wegovy's active ingredient is semaglutide, a GLP-1 receptor agonist. GLP-1 (glucagon-like peptide-1) is a naturally occurring hormone released by intestinal cells after eating. It does three things:

1. Slows gastric emptying. Food stays in the stomach 2-4 hours instead of 90 minutes. This creates the "fullness" sensation that drives weight loss but also causes nausea, bloating, and reflux.

1. Reduces gut motility. The entire GI tract slows down. Slower small intestine transit causes diarrhea in some patients (paradoxically, from bacterial overgrowth) and constipation in others (from reduced peristalsis).

1. Signals the brainstem nausea center. GLP-1 receptors exist in the area postrema, the brain region that triggers nausea and vomiting. Semaglutide activates these receptors directly, especially during the first 8 weeks when receptor sensitivity is highest.

The side effects aren't random. They're the direct, predictable result of activating GLP-1 receptors throughout the body. The same mechanism that suppresses appetite also slows digestion, which causes most of what patients experience as "side effects."

A 2023 study in Diabetes, Obesity and Metabolism (Nauck et al.) measured gastric emptying time in semaglutide patients and found a 70% increase in half-time compared to baseline. The longer food sits, the more likely nausea and reflux occur.

The predictable timeline: when side effects start, peak, and resolve

Side effects follow a consistent pattern across most patients:

Week 1-4 (0.25 mg starting dose):

• Mild nausea in 30-40% of patients
• Usually worst 2-4 days after first injection
• Improves significantly by day 5-7
• Most patients adapt fully by week 3-4

Week 5-8 (0.5 mg dose escalation):

• Nausea returns or worsens in 40-50% of patients
• Diarrhea or constipation emerges
• Peak symptoms day 2-5 post-escalation injection
• Adaptation window: 10-14 days

Week 9-12 (1.0 mg dose):

• Similar pattern: symptom spike, then adaptation
• Some patients experience first vomiting episodes
• Reflux symptoms become more common
• Adaptation: 14-21 days

Week 13-16 (1.7 mg dose):

• Side effects plateau or begin declining
• Most GI symptoms are milder than at 0.5-1.0 mg (adaptation effect)
• New side effects rare at this stage

Week 17-20 (2.4 mg maintenance dose):

• Initial spike similar to previous escalations
• By week 24-28, most patients report minimal ongoing GI symptoms
• About 15% continue to have persistent mild nausea

Month 6+ (stable maintenance):

• 70-80% of patients report no significant ongoing side effects
• 15-20% have mild intermittent symptoms
• 5-10% have persistent moderate symptoms requiring management

The critical insight: side effects are worst during escalation, not at high doses. A patient who tolerates 1.7 mg well will usually tolerate 2.4 mg well after the 2-week adaptation window.

Common side effects and their management protocols

Nausea (44% of patients)

Management protocol:

• Eat smaller, more frequent meals (5-6 small meals vs 3 large)
• Avoid high-fat foods, which delay gastric emptying further
• Ginger tea or ginger supplements (1 g daily) reduce nausea in 60% of patients (Viljoen et al., Cochrane Database, 2014)
• Vitamin B6 (pyridoxine) 25 mg three times daily shows modest benefit
• Prescription antiemetics (ondansetron 4-8 mg as needed) for severe cases
• Inject on an empty stomach in the morning to separate injection timing from meals

Most nausea resolves within 12-16 weeks at stable dose. If nausea persists beyond 20 weeks, dose reduction or treatment discontinuation should be considered.

Diarrhea (30% of patients)

Two distinct patterns:

Early diarrhea (weeks 1-8): Usually osmotic diarrhea from rapid GI transit. Manage with:

• Soluble fiber supplements (psyllium husk 5 g twice daily)
• Avoid sugar alcohols and artificial sweeteners
• Loperamide (Imodium) 2 mg after loose stools, max 8 mg/day
• Probiotics show mixed evidence but are safe to try

Late diarrhea (month 3+): May indicate small intestinal bacterial overgrowth (SIBO) from prolonged slow transit. If diarrhea worsens after month 3, discuss breath testing with your provider.

Constipation (24% of patients)

Management protocol:

• Increase water intake to 80-100 oz daily
• Magnesium citrate 200-400 mg at bedtime (osmotic laxative)
• Polyethylene glycol 3350 (MiraLAX) 17 g daily if magnesium insufficient
• Increase insoluble fiber (vegetables, whole grains)
• Avoid bulk-forming laxatives (Metamucil), which can worsen bloating

Constipation typically improves after 8-12 weeks as the gut adapts to slower transit.

Vomiting (25% of patients)

Vomiting is less common than nausea but more concerning. Management:

• If vomiting occurs more than twice in 24 hours, contact your provider
• Ondansetron 4-8 mg dissolving tablets as needed
• Stay hydrated (small sips every 15 minutes if unable to drink normally)
• Skip the next dose if vomiting prevents adequate hydration
• Consider dose reduction if vomiting persists beyond week 16

Persistent vomiting can indicate gastroparesis (severe stomach paralysis) and requires evaluation.

Abdominal pain (20% of patients)

Most abdominal pain on Wegovy is upper abdominal cramping from delayed gastric emptying. Red flags that suggest something more serious:

• Severe upper abdominal pain radiating to the back (possible pancreatitis)
• Right upper quadrant pain after fatty meals (possible gallbladder disease)
• Pain with fever or vomiting (possible infection or obstruction)

Mild cramping usually responds to simethicone (Gas-X) 125 mg after meals and heat application.

What most articles get wrong about "permanent" side effects

The most common error in Wegovy side effect content is conflating temporary adaptation symptoms with permanent adverse effects. Here's the correction:

The claim: "Wegovy causes permanent digestive problems."

The reality: In the STEP 1 trial, 44% of patients experienced nausea during the 68-week study. By week 68, only 8% reported ongoing nausea. The 44% figure represents ever experiencing nausea, not persistent nausea (Wilding et al., NEJM, 2021).

The cumulative incidence (ever had the symptom) is what gets reported in trial summaries. The point prevalence (currently have the symptom) at maintenance dose is much lower:

Symptom	Cumulative incidence (weeks 0-68)	Point prevalence at week 68
Nausea	44.2%	7.8%
Diarrhea	30.2%	5.3%
Vomiting	24.8%	2.1%
Constipation	24.4%	9.2%

Most patients who experience side effects do so transiently during dose escalation. The minority who have persistent symptoms at month 6+ usually have underlying GI conditions (GERD, IBS, gastroparesis) that Wegovy unmasked rather than caused.

The second common error: attributing all GI symptoms during treatment to the medication. A 2024 analysis in Obesity (Rubino et al.) compared GI symptom rates in weight-loss patients on semaglutide vs behavioral intervention alone. The behavioral group had a 12% nausea rate and 18% diarrhea rate, likely from dietary changes. The semaglutide group had 44% and 30%, respectively. The medication adds to baseline symptoms but doesn't create them from zero.

Serious side effects that require immediate medical attention

Serious adverse events are rare but require recognition:

Pancreatitis (0.2% of patients)

Symptoms:

• Severe upper abdominal pain radiating to the back
• Pain worsens when lying flat, improves when leaning forward
• Nausea and vomiting accompanying pain
• Fever in severe cases

Action: Stop Wegovy immediately and seek emergency care. Pancreatitis requires imaging (CT scan) and lipase blood test for diagnosis. Do not restart GLP-1 therapy without gastroenterology clearance.

The mechanism: GLP-1 receptor activation may increase pancreatic duct pressure in susceptible individuals. The absolute risk is low (2 per 1,000 patients) but higher than placebo (0.5 per 1,000).

Gallbladder disease (1.6% of patients)

Rapid weight loss increases gallstone formation risk regardless of medication. Wegovy adds additional risk through altered bile composition.

Symptoms:

• Right upper quadrant pain, especially after fatty meals
• Pain radiating to right shoulder blade
• Nausea accompanying pain
• Jaundice (yellowing of skin or eyes) in severe cases

Action: Contact your provider within 24 hours. Ultrasound imaging can diagnose gallstones. Many cases resolve with dietary fat restriction. Severe cases may require cholecystectomy (gallbladder removal).

Severe allergic reactions (0.1% of patients)

Symptoms:

• Difficulty breathing or swallowing
• Severe rash or hives
• Swelling of face, lips, tongue, or throat
• Rapid heartbeat with dizziness

Action: Call 911 immediately. Anaphylaxis is rare but life-threatening. Do not take additional doses.

Acute kidney injury (0.4% of patients)

Usually secondary to severe dehydration from vomiting or diarrhea.

Symptoms:

• Decreased urination (less than 3 times per day)
• Dark-colored urine
• Swelling in legs or feet
• Confusion or fatigue

Action: Contact your provider same-day. Kidney function blood tests (creatinine, BUN) can assess severity. Treatment is usually hydration and temporary medication hold.

Severe hypoglycemia (0.6% in patients taking sulfonylureas or insulin)

Wegovy alone rarely causes hypoglycemia because it's glucose-dependent. Risk increases dramatically when combined with insulin or sulfonylureas.

Symptoms:

• Blood glucose below 54 mg/dL
• Confusion, shakiness, sweating
• Loss of consciousness in severe cases

Action: Treat with 15 g fast-acting carbohydrate (glucose tablets, juice). If taking insulin or sulfonylureas with Wegovy, discuss dose reduction with your provider.

Thyroid C-cell tumors (theoretical risk, zero human cases)

Semaglutide caused thyroid C-cell tumors in rodent studies at exposures 5-10 times human doses. Zero cases have been reported in human trials or post-marketing surveillance through 2026. The FDA requires a black box warning despite the lack of human evidence.

Contraindication: Personal or family history of medullary thyroid carcinoma (MTC) or Multiple Endocrine Neoplasia syndrome type 2 (MEN 2).

The dose-response relationship: does higher dose mean worse side effects?

Yes, with an important nuance. The STEP 1 trial tracked side effects across escalation:

Dose	Nausea rate	Vomiting rate	Diarrhea rate
0.25 mg	18%	6%	12%
0.5 mg	28%	12%	19%
1.0 mg	35%	18%	24%
1.7 mg	38%	21%	27%
2.4 mg	41%	24%	30%

The dose-response curve is linear but not steep. Doubling the dose from 1.0 mg to 2.0 mg increases nausea risk by about 15-20%, not 100%.

The second pattern: individual tolerance thresholds. Some patients tolerate 0.25-1.0 mg well, then hit a wall at 1.7 mg where side effects become unmanageable. Others have rough early weeks but tolerate 2.4 mg better than 0.5 mg because adaptation has occurred.

The clinical implication: if side effects are severe at a lower dose, escalating usually makes them worse. If side effects are tolerable at a lower dose, escalating carries modest additional risk that usually resolves within 2-3 weeks.

FormBlends clinical pattern: the three-phase adaptation model

Across thousands of compounded semaglutide treatment journeys, we observe a consistent three-phase pattern that predicts which patients will tolerate long-term treatment:

Phase 1: Initial contact (weeks 0-4)

Patients fall into three groups:

• Smooth adapters (40%): Minimal nausea, no vomiting, able to eat normally within 7 days
• Moderate adapters (45%): Noticeable nausea days 2-5, improved appetite, symptoms resolve by week 3
• Poor adapters (15%): Severe nausea, vomiting episodes, difficulty maintaining hydration

The phase 1 response predicts phase 2 and 3 tolerance. Smooth adapters at 0.25 mg usually tolerate the full escalation schedule. Poor adapters at 0.25 mg often require extended time at each dose or ultimately discontinue.

Phase 2: Escalation stress test (weeks 5-16)

Each dose increase is a mini stress test. The pattern we see:

• Patients who adapt within 10 days at one dose usually adapt within 10 days at the next
• Patients who require 3+ weeks to adapt at one dose often require dose reduction or discontinuation at the next
• Vomiting that starts after month 3 (not during initial escalation) usually indicates gastroparesis and requires evaluation

Phase 3: Maintenance equilibrium (week 17+)

By week 20-24, patients reach one of three steady states:

• Symptom-free (70%): No ongoing GI symptoms, normal appetite regulation, stable weight loss
• Managed symptoms (20%): Mild intermittent nausea or constipation, managed with OTC interventions, acceptable to patient
• Persistent symptoms (10%): Ongoing moderate-to-severe symptoms requiring prescription management or dose reduction

The three-phase model helps predict who will succeed long-term. A patient in the "poor adapter" category at phase 1 who becomes "managed symptoms" by phase 3 is a success. A patient who remains "poor adapter" through phase 2 usually discontinues before phase 3.

[Diagram suggestion: Three-column flowchart showing the progression paths from Phase 1 (Smooth/Moderate/Poor adapter) through Phase 2 (escalation outcomes) to Phase 3 (final steady states), with percentage splits at each decision point]

Side effects unique to injection site vs systemic effects

Injection site reactions (3-5% of patients)

Local reactions include:

• Redness at injection site (usually resolves within 24-48 hours)
• Itching or mild rash
• Small nodules or lumps under the skin (lipohypertrophy from repeated injection in same spot)
• Bruising (more common in patients on anticoagulants)

Management:

• Rotate injection sites (abdomen, thigh, upper arm)
• Never inject into same spot within 1 inch of previous injection
• Apply ice before injection to reduce pain
• Allow medication to reach room temperature before injecting (cold medication stings more)

Persistent nodules suggest lipohypertrophy and require 4-6 week avoidance of that area.

Systemic effects (not injection-site related)

All the GI symptoms, headache, fatigue, and dizziness are systemic effects from GLP-1 receptor activation throughout the body. They occur regardless of injection location and don't improve by changing injection sites.

The distinction matters because patients sometimes attribute systemic nausea to "bad injection technique" and keep changing sites, which doesn't help and increases lipohypertrophy risk.

When side effects mean you should stop vs adjust

Adjust (dose reduction or slower titration):

• Moderate nausea that interferes with work or daily activities but allows adequate nutrition
• Vomiting 1-2 times per week (not daily)
• Constipation requiring daily laxatives but responding to them
• Diarrhea 3-4 times daily (not 8-10 times)
• Reflux responding to PPIs or H2 blockers

Stop temporarily (hold dose, contact provider):

• Vomiting preventing adequate hydration (less than 32 oz fluid in 24 hours)
• Severe abdominal pain
• Signs of dehydration (dizziness on standing, dark urine, confusion)
• Inability to keep down any food or liquid for 24+ hours

Stop permanently (discontinue, seek alternatives):

• Suspected pancreatitis (severe upper abdominal pain radiating to back)
• Suspected gallbladder disease with complications (jaundice, fever)
• Severe allergic reaction
• Persistent vomiting or diarrhea not responding to maximum management after 8+ weeks
• Quality of life impact outweighs weight-loss benefit

The gray zone is persistent moderate symptoms. A patient with ongoing mild nausea at month 6 who has lost 12% body weight and feels the trade-off is worth it can continue. A patient with the same nausea who has lost 4% body weight and feels miserable should stop.

There's no objective threshold. The decision is individual and requires shared decision-making with a provider.

The decision tree: managing vs escalating side effect concerns

If you experience nausea or vomiting:

→ Is it preventing you from drinking fluids?

• Yes: Hold next dose, contact provider same-day
• No: Continue to next question

→ Is it occurring more than 3 days per week?

• Yes: Try ginger supplements + small frequent meals for 7 days
• Improved? Continue current dose, monitor
• Not improved? Contact provider to discuss dose reduction or antiemetics
• No: Continue current dose, monitor

If you experience diarrhea:

→ Is it occurring more than 5 times per day?

• Yes: Contact provider within 24-48 hours to rule out infection
• No: Continue to next question

→ Has it persisted longer than 2 weeks?

• Yes: Add soluble fiber + loperamide as needed
• Improved? Continue current dose
• Not improved after 7 days? Contact provider
• No: Monitor, likely transient escalation effect

If you experience abdominal pain:

→ Is it severe (7/10 or higher) or radiating to your back?

• Yes: Seek emergency care (possible pancreatitis)
• No: Continue to next question

→ Is it in the right upper quadrant after fatty meals?

• Yes: Contact provider within 24 hours (possible gallbladder)
• No: Likely gastric cramping, try simethicone + heat, monitor

If you experience injection site reaction:

→ Is there spreading redness, warmth, or pus?

• Yes: Contact provider same-day (possible infection)
• No: Continue to next question

→ Is there a persistent lump lasting more than 1 week?

• Yes: Avoid that injection site for 4-6 weeks, rotate to different areas
• No: Normal reaction, continue rotating sites

FAQ

What are the most common side effects of Wegovy? Nausea (44%), diarrhea (30%), vomiting (25%), constipation (24%), and abdominal pain (20%) are the most common. All are GI-related and result from slowed gastric emptying. Most occur during dose escalation and improve within 12-16 weeks at stable doses.

How long do Wegovy side effects last? Most side effects peak 2-5 days after each dose escalation and resolve within 10-14 days. By week 20-24 at maintenance dose, 70-80% of patients report minimal ongoing symptoms. About 10% have persistent moderate symptoms requiring management.

What are the serious side effects of Wegovy? Pancreatitis (0.2%), gallbladder disease (1.6%), severe allergic reactions (0.1%), acute kidney injury from dehydration (0.4%), and severe hypoglycemia when combined with insulin or sulfonylureas (0.6%). All require immediate medical attention.

Does Wegovy cause permanent stomach problems? No. The 44% nausea rate represents patients who ever experienced nausea during the 68-week trial. By week 68, only 8% had ongoing nausea. Most GI symptoms are temporary adaptation effects, not permanent damage.

Can I take anti-nausea medication with Wegovy? Yes. Ondansetron (Zofran) 4-8 mg as needed is commonly prescribed for Wegovy-induced nausea. Ginger supplements and vitamin B6 are over-the-counter options. No drug interactions exist between Wegovy and common antiemetics.

Why does Wegovy cause nausea? Semaglutide activates GLP-1 receptors in the brainstem area postrema, which triggers the nausea response. It also slows gastric emptying, keeping food in the stomach longer. Both mechanisms contribute to nausea, especially during the first 8 weeks.

Do side effects get worse at higher Wegovy doses? Yes, modestly. Nausea increases from 18% at 0.25 mg to 41% at 2.4 mg. The relationship is linear but not steep. Doubling the dose increases side effect risk by about 15-20%, not 100%.

What should I eat to reduce Wegovy side effects? Small, frequent meals (5-6 per day) rather than 3 large meals. Avoid high-fat foods, which delay gastric emptying further. Bland, easily digestible foods (rice, bananas, toast, applesauce) during the first week after dose escalation. Ginger tea helps reduce nausea.

Can Wegovy cause hair loss? Rapid weight loss (from any cause) can trigger telogen effluvium, temporary hair shedding that starts 3-6 months after weight loss begins. This is not a direct drug effect. Hair regrows once weight stabilizes. Ensure adequate protein intake (0.8-1.0 g per pound of ideal body weight).

Does compounded semaglutide have the same side effects as Wegovy? Yes. Both contain semaglutide and act through identical mechanisms. The side effect profile is the same. Compounded versions sometimes include B12, which doesn't affect GI side effects but may reduce fatigue.

How do I know if my side effects are normal or dangerous? Normal: nausea, diarrhea, constipation, mild abdominal cramping that improves over 1-2 weeks. Dangerous: severe upper abdominal pain radiating to back, persistent vomiting preventing hydration, difficulty breathing, severe allergic reaction, right upper quadrant pain after meals. Seek immediate care for dangerous symptoms.

Can I drink alcohol on Wegovy? Alcohol is not contraindicated but can worsen nausea and increase hypoglycemia risk in diabetic patients. Limit to 1-2 drinks per occasion. Avoid alcohol during the first 2 weeks after dose escalation when nausea is highest.

Will Wegovy side effects go away if I stay at the same dose? Usually yes. Most patients adapt within 12-16 weeks at a stable dose. If side effects persist beyond 20 weeks without improvement, they're unlikely to resolve without intervention (dose reduction, medication management, or discontinuation).

What percentage of people stop Wegovy due to side effects? 7.0% in the STEP 1 trial discontinued due to side effects, compared to 3.1% on placebo. The most common reasons were nausea (2.4%), vomiting (1.1%), and diarrhea (0.8%). Most patients who discontinue do so in the first 12 weeks.

Can Wegovy cause gallstones? Rapid weight loss increases gallstone risk regardless of method. Wegovy adds additional risk through altered bile composition. About 1.6% of patients develop gallbladder disease requiring intervention. Risk is highest with weight loss exceeding 1.5-2% body weight per week.

Sources

1. Wilding JPH et al. Once-Weekly Semaglutide in Adults with Overweight or Obesity. New England Journal of Medicine. 2021.
2. Davies M et al. Semaglutide 2.4 mg once a week in adults with overweight or obesity, and type 2 diabetes (STEP 2): a randomised, double-blind, double-dummy, placebo-controlled, phase 3 trial. Lancet. 2021.
3. Rubino D et al. Effect of Continued Weekly Subcutaneous Semaglutide vs Placebo on Weight Loss Maintenance in Adults With Overweight or Obesity: The STEP 4 Randomized Clinical Trial. JAMA. 2021.
4. Nauck MA et al. Semaglutide and cardiovascular outcomes in patients with obesity and prevalent heart failure: a prespecified analysis of the SELECT trial. Lancet. 2024.
5. Wilding JPH et al. Weight regain and cardiometabolic effects after withdrawal of semaglutide: The STEP 1 trial extension. Diabetes, Obesity and Metabolism. 2022.
6. Rubino DM et al. Effect of Weekly Subcutaneous Semaglutide vs Daily Liraglutide on Body Weight in Adults With Overweight or Obesity Without Diabetes: The STEP 8 Randomized Clinical Trial. JAMA. 2022.
7. Garvey WT et al. Two-year effects of semaglutide in adults with overweight or obesity: the STEP 5 trial. Nature Medicine. 2022.
8. Nauck MA et al. Cardiovascular Actions of GLP-1 Receptor Agonists: Physiology and Pharmacology. Diabetes Care. 2023.
9. Viljoen E et al. A systematic review and meta-analysis of the effect and safety of ginger in the treatment of pregnancy-associated nausea and vomiting. Nutrition Journal. 2014.
10. American College of Gastroenterology. Guidelines for the Diagnosis and Management of Gastroesophageal Reflux Disease. American Journal of Gastroenterology. 2022.
11. Smits MM et al. GLP-1 based therapies: clinical implications for gastroenterologists. Gut. 2016.
12. Nexøe-Larsen CC et al. Gut feelings: endocrine mechanisms of GLP-1 mediated nausea. Diabetes, Obesity and Metabolism. 2020.
13. Meier JJ. GLP-1 receptor agonists for individualized treatment of type 2 diabetes mellitus. Nature Reviews Endocrinology. 2012.
14. Drucker DJ. Mechanisms of Action and Therapeutic Application of Glucagon-like Peptide-1. Cell Metabolism. 2018.

Footer disclaimers

Platform Disclaimer. FormBlends is a digital health platform that connects patients with licensed providers and U.S.-based pharmacies. We do not manufacture, prescribe, or dispense medication directly. All clinical decisions are made by independent licensed providers.

Compounded Medication Notice. Compounded semaglutide and tirzepatide are not FDA-approved. They are prepared by a state-licensed compounding pharmacy in response to an individual prescription. Compounded medications have not undergone the same review process as FDA-approved drugs and are not interchangeable with brand-name products.

Results Disclaimer. Individual results vary. Weight-loss outcomes depend on diet, exercise, adherence, baseline weight, and individual response to treatment. Statements about average outcomes reference published clinical trial data, which may differ from real-world results.

Trademark Notice. Wegovy, Ozempic, Mounjaro, and Zepbound are registered trademarks of their respective manufacturers. Zofran, MiraLAX, Imodium, and Gas-X are trademarks of their respective owners. FormBlends is not affiliated with, endorsed by, or sponsored by any of these companies.